JP6951417B2 - アフィニティークロマトグラフィーのためのＦＣ−結合タンパク質、並びにＦｃ−結合タンパク質を含むアフィニティー分離マトリックスおよびその使用 - Google Patents

アフィニティークロマトグラフィーのためのＦＣ−結合タンパク質、並びにＦｃ−結合タンパク質を含むアフィニティー分離マトリックスおよびその使用 Download PDF

Info

Publication number
JP6951417B2
JP6951417B2 JP2019507171A JP2019507171A JP6951417B2 JP 6951417 B2 JP6951417 B2 JP 6951417B2 JP 2019507171 A JP2019507171 A JP 2019507171A JP 2019507171 A JP2019507171 A JP 2019507171A JP 6951417 B2 JP6951417 B2 JP 6951417B2
Authority
JP
Japan
Prior art keywords
protein
binding
binding protein
affinity
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019507171A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527715A (ja
Inventor
ニック、ポール
フィードラー、エリック
ハウプトス、ウルリッヒ
メイシング、マレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Repligen Corp
Original Assignee
Repligen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repligen Corp filed Critical Repligen Corp
Publication of JP2019527715A publication Critical patent/JP2019527715A/ja
Application granted granted Critical
Publication of JP6951417B2 publication Critical patent/JP6951417B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
    • B01J20/26—Synthetic macromolecular compounds
    • B01J20/262—Synthetic macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. obtained by polycondensation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2221/00—Applications of separation devices
    • B01D2221/10—Separation devices for use in medical, pharmaceutical or laboratory applications, e.g. separating amalgam from dental treatment residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
JP2019507171A 2016-08-11 2017-08-07 アフィニティークロマトグラフィーのためのＦＣ−結合タンパク質、並びにＦｃ−結合タンパク質を含むアフィニティー分離マトリックスおよびその使用 Active JP6951417B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16183710 2016-08-11
EP16183710.9 2016-08-11
EP16205707.9 2016-12-21
EP16205707 2016-12-21
PCT/EP2017/069979 WO2018029158A1 (en) 2016-08-11 2017-08-07 Alkaline stable fc—binding proteins for affinity chromatography

Publications (2)

Publication Number Publication Date
JP2019527715A JP2019527715A (ja) 2019-10-03
JP6951417B2 true JP6951417B2 (ja) 2021-10-20

Family

ID=59631752

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019507171A Active JP6951417B2 (ja) 2016-08-11 2017-08-07 アフィニティークロマトグラフィーのためのＦＣ−結合タンパク質、並びにＦｃ−結合タンパク質を含むアフィニティー分離マトリックスおよびその使用
JP2019505354A Active JP7181612B2 (ja) 2016-08-11 2017-08-07 アルカリ安定性免疫グロブリン結合タンパク質
JP2022112299A Pending JP2022160444A (ja) 2016-08-11 2022-07-13 アルカリ安定性免疫グロブリン結合タンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019505354A Active JP7181612B2 (ja) 2016-08-11 2017-08-07 アルカリ安定性免疫グロブリン結合タンパク質
JP2022112299A Pending JP2022160444A (ja) 2016-08-11 2022-07-13 アルカリ安定性免疫グロブリン結合タンパク質

Country Status (11)

Country Link
US (4) US11014967B2 (enExample)
EP (4) EP3497117B1 (enExample)
JP (3) JP6951417B2 (enExample)
KR (3) KR102578256B1 (enExample)
CN (4) CN117736281A (enExample)
AU (2) AU2017311541B2 (enExample)
CA (2) CA3030208A1 (enExample)
DK (1) DK3497117T5 (enExample)
LT (1) LT3497117T (enExample)
SG (1) SG11201901066UA (enExample)
WO (2) WO2018029157A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6738340B2 (ja) 2015-02-06 2020-08-12 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ 新規なｅｇｆｒ結合タンパク質
ES2916101T3 (es) 2015-07-16 2022-06-28 Navigo Proteins Gmbh Nuevas proteínas de unión a inmunoglobulina y su uso en la purificación por afinidad
JP2018520675A (ja) 2015-07-20 2018-08-02 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法
JP2019526526A (ja) 2016-05-04 2019-09-19 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ ペプチドリンカーを含む化学的部分の部位特異的カップリングのための標的化合物
DK3497117T5 (da) * 2016-08-11 2024-09-02 Navigo Proteins Gmbh Nye alkalisk stabile immunglobulin-bindende proteiner
EP3521304B9 (en) * 2018-02-01 2023-10-04 Repligen Corporation Fc binding proteins with cysteine in the c-terminal helical region
CN111132994B (zh) * 2017-08-07 2024-05-31 瑞普利金公司 在c末端螺旋区中具有半胱氨酸的fc结合蛋白
EP3546476A1 (en) * 2018-03-26 2019-10-02 Repligen Corporation Fc binding proteins with cysteine in the c-terminal helical region
EP3706804B1 (en) 2017-11-07 2022-02-23 Navigo Proteins GmbH Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
EP4349853A3 (en) * 2018-11-12 2024-07-03 Navigo Proteins Gmbh Novel triple-helical polypeptides lacking binding affinity for the fc domain of immunoglobulin and uses thereof
EP3650465A1 (en) * 2018-11-12 2020-05-13 Navigo Proteins Gmbh Novel populations of polypeptides having a triple-helical structure
BR112021013026A2 (pt) * 2019-02-01 2021-10-13 Navigo Proteins Gmbh Proteínas de ligação à imunoglobulina, matriz de separação por afinidade, uso da proteína de ligação à imunoglobulina, e método de purificação por afinidade de uma proteína compreendendo uma sequência de imunoglobulina
GB201904125D0 (en) 2019-03-26 2019-05-08 Ge Healthcare Bio Sciences Ab Method for sanitization of a chromatography column
JP7432813B2 (ja) * 2019-09-10 2024-02-19 東ソー株式会社 免疫グロブリン結合性タンパク質
WO2021122943A1 (en) * 2019-12-17 2021-06-24 Navigo Proteins Gmbh Binding proteins for the enzyme acid alpha glucosidase (gaa) and uses thereof
US20230093429A1 (en) * 2020-02-21 2023-03-23 Navigo Proteins Gmbh AFFINITY LIGAND FOR THE SOLUBLE PART OF FIBROBLAST GROWTH FACTOR RECEPTOR 3 (sFGFR3)
EP3875472A1 (en) * 2020-03-06 2021-09-08 Navigo Proteins Gmbh Novel immunoglobulin binding polypeptides
EP4168439B1 (en) * 2020-06-23 2024-07-31 Navigo Proteins Gmbh Binding protein specific for the spike protein of severe acute respiratory syndrome corona virus 2 (sars-cov-2)
CA3184992A1 (en) * 2020-07-15 2022-01-20 Paul KNICK Immunoglobulin binding proteins for affinity purification
WO2022096738A1 (en) * 2020-11-09 2022-05-12 Navigo Proteins Gmbh Novel type ii collagen binding proteins
EP4001301A1 (en) * 2020-11-13 2022-05-25 Navigo Proteins Gmbh Binding protein for complement factor h (cfh)
EP4380955A1 (en) * 2021-08-06 2024-06-12 Roche Diagnostics GmbH Chimeric igg-fc-binding ligand polypeptide and uses thereof for igg affinity purification
GB202113626D0 (en) 2021-09-24 2021-11-10 Cytiva Bioprocess R & D Ab FC binding polypeptides
CN116925197A (zh) * 2021-12-21 2023-10-24 百林科(兰州)新材料有限公司 耐碱蛋白A变体在纯化IgG抗体中的应用
CN113999294B (zh) * 2021-12-30 2022-03-29 苏州纳微科技股份有限公司 免疫球蛋白结合蛋白及其应用
CN114409748A (zh) * 2022-01-28 2022-04-29 博格隆(浙江)生物技术有限公司 蛋白a的b结构域和z结构域突变体及其应用
GB202203478D0 (en) 2022-03-14 2022-04-27 Cytiva Bioprocess R & D Ab Vh3 binding polypeptides
EP4634208A1 (en) * 2022-12-16 2025-10-22 Navigo Proteins Gmbh New ligands for affinity chromatography
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
EP4541444A1 (en) * 2023-10-20 2025-04-23 Cytiva BioProcess R&D AB Fusion protein for affinity capture

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
US5629167A (en) * 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
EP0729513B1 (en) * 1994-07-21 2004-06-02 Aventis Pasteur Limited Analog of haemophilus hin47 with reduced protease activity
WO1997012992A2 (en) 1995-10-02 1997-04-10 Royal Netherlands Academy Of Arts And Sciences Diagnosis method for a disease caused by a frameshift mutation in a gene and reagents therefore
WO1997016556A1 (en) 1995-10-30 1997-05-09 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase i
US5789166A (en) 1995-12-08 1998-08-04 Stratagene Circular site-directed mutagenesis
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
FR2761689B1 (fr) 1997-04-02 1999-06-25 Transgene Sa Fibre adenovirale modifiee et adenovirus cibles
ES2209145T5 (es) 1997-05-28 2009-10-30 Crescendo Biologics Ltd. Complejos de ribosomas como particulas de seleccion para el desarrollo in vitro y evolucion de proteinas.
EP0985039B1 (en) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US20030045681A1 (en) 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
CA2399866C (en) 2000-02-24 2011-05-10 Philogen S.R.L. Compositions and methods for treatment of angiogenesis in pathological lesions
EP1259548A1 (en) 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
US6799121B2 (en) 2000-03-30 2004-09-28 York University Sequencing of peptides by mass spectrometry
US20110179531A1 (en) 2000-05-09 2011-07-21 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US20030073623A1 (en) 2001-07-30 2003-04-17 Drmanac Radoje T. Novel nucleic acid sequences obtained from various cDNA libraries
JP4460302B2 (ja) 2002-02-05 2010-05-12 ジェネンテック インコーポレイテッド タンパク質精製法
SE0200943D0 (sv) * 2002-03-25 2002-03-25 Amersham Biosciences Ab Mutant protein
US20040043386A1 (en) 2002-08-30 2004-03-04 Todd Pray Methods and compositions for functional ubiquitin assays
EP1591527B1 (en) 2003-01-23 2015-08-26 Ono Pharmaceutical Co., Ltd. Substance specific to human pd-1
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
WO2005044845A2 (en) 2003-11-04 2005-05-19 Yale University Protein binding miniature proteins
US7393918B2 (en) 2003-12-11 2008-07-01 Yale University Protein binding miniature proteins and uses thereof
DE10360483B4 (de) 2003-12-22 2007-11-15 Scil Proteins Gmbh Expressionsvektor und dessen Verwendung
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
DE102004049479A1 (de) 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
JP2006304633A (ja) * 2005-04-26 2006-11-09 Apro Life Science Institute Inc イムノグロブリン結合タンパク質
CA2607954A1 (en) 2005-05-11 2006-11-16 Philogen S.P.A. Conjugate for targeting of drug
MY185597A (en) * 2005-09-20 2021-05-24 Avantor Performance Mat Inc Vegetarian protein a preparation and methods thereof
BRPI0520677A2 (pt) 2005-11-09 2009-05-19 Bayer Schering Pharma Ag identificação e caracterização de anticorpos de função de bloqueio anti-ed-b-fibronectina
EP1842553A1 (en) 2006-04-07 2007-10-10 Bayer Schering Pharma Aktiengesellschaft Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule
JP2009536170A (ja) 2006-05-08 2009-10-08 フィロジェン・エッセペア 治療用の抗体標的指向サイトカイン
EP1892248A1 (en) 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
JP5345539B2 (ja) * 2006-09-29 2013-11-20 ジーイー・ヘルスケア・バイオ−サイエンシズ・アーベー 抗体単離のためのスタフィロコッカスアウレウス由来のドメインｃを含むクロマトグラフィーリガンド
EP1925664A1 (en) 2006-11-15 2008-05-28 Scil proteins GmbH Artificial binding proteins based on a modified alpha helical region of ubiquitin
EP1955712A1 (en) 2007-02-09 2008-08-13 Scil proteins GmbH Multimeric conjugate
PL2310509T3 (pl) 2008-07-21 2015-08-31 Apogenix Ag Jednołańcuchowe cząsteczki TNFSF
US8592555B2 (en) * 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
BR112012014194A2 (pt) 2009-12-14 2017-01-10 Scil Proteins Gmbh um método para identificar proteínas ubiquitinas modificadas hetero-multiméricas com capacidade de ligação a ligandos
JP5952185B2 (ja) * 2010-03-24 2016-07-13 株式会社カネカ 免疫グロブリンに特異的に結合するタンパク質および免疫グロブリン結合性アフィニティーリガンド
US10065995B2 (en) * 2011-03-25 2018-09-04 Kaneka Corporation Protein for affinity-separation matrix
SG10201604554WA (en) 2011-06-08 2016-07-28 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
EP2721152B1 (en) 2011-06-15 2019-03-27 Navigo Proteins GmbH Dimeric binding proteins based on modified ubiquitins
WO2012171541A1 (en) 2011-06-15 2012-12-20 Scil Proteins Gmbh Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
US20150183846A1 (en) 2012-06-13 2015-07-02 Scil Proteins Gmbh Human fusion proteins comprising single chain tnfalpha and targeting domains
US9920098B2 (en) 2012-09-21 2018-03-20 Kaneka Corporation Protein ligand for affinity isolation matrix
EP2727942A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Bispecific antibodies against human EGFR, HER2, and HER3
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
WO2014094799A1 (en) 2012-12-19 2014-06-26 Scil-Proteins-Gmbh Ubiquitin moieties as a means for prolonging serum half-life
US9896486B2 (en) * 2013-07-10 2018-02-20 Ge Healthcare Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
KR102236367B1 (ko) 2013-07-26 2021-04-05 삼성전자주식회사 DARPin을 포함하는 이중 특이 키메라 단백질
US11566082B2 (en) * 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
EP3253795B1 (en) 2015-02-06 2019-04-17 Navigo Proteins Gmbh Novel binding proteins comprising a ubiquitin mutein and antibodies or antibody fragments
JP6738340B2 (ja) 2015-02-06 2020-08-12 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ 新規なｅｇｆｒ結合タンパク質
ES2916101T3 (es) 2015-07-16 2022-06-28 Navigo Proteins Gmbh Nuevas proteínas de unión a inmunoglobulina y su uso en la purificación por afinidad
JP2018520675A (ja) 2015-07-20 2018-08-02 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法
CA2991814A1 (en) 2015-07-20 2017-01-26 Navigo Proteins Gmbh Her2 binding proteins based on di-ubiquitin muteins
JP2019526526A (ja) 2016-05-04 2019-09-19 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ ペプチドリンカーを含む化学的部分の部位特異的カップリングのための標的化合物
DK3497117T5 (da) 2016-08-11 2024-09-02 Navigo Proteins Gmbh Nye alkalisk stabile immunglobulin-bindende proteiner
CN111132994B (zh) 2017-08-07 2024-05-31 瑞普利金公司 在c末端螺旋区中具有半胱氨酸的fc结合蛋白
EP3521304B9 (en) 2018-02-01 2023-10-04 Repligen Corporation Fc binding proteins with cysteine in the c-terminal helical region
EP3706804B1 (en) 2017-11-07 2022-02-23 Navigo Proteins GmbH Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer

Also Published As

Publication number Publication date
DK3497117T3 (da) 2024-04-22
CA3030208A1 (en) 2018-02-15
US20210206815A1 (en) 2021-07-08
AU2017311541A1 (en) 2019-02-21
JP2022160444A (ja) 2022-10-19
CN109476712B (zh) 2022-08-02
JP7181612B2 (ja) 2022-12-01
JP2019531055A (ja) 2019-10-31
EP3497117B1 (en) 2024-01-24
WO2018029158A1 (en) 2018-02-15
US20190177376A1 (en) 2019-06-13
LT3497117T (lt) 2024-05-10
KR20190038560A (ko) 2019-04-08
KR102578256B1 (ko) 2023-09-15
CN109963864B (zh) 2024-01-02
WO2018029157A1 (en) 2018-02-15
AU2017311542A1 (en) 2019-02-07
AU2017311542B2 (en) 2021-06-24
CN117736281A (zh) 2024-03-22
EP3497117A1 (en) 2019-06-19
US11230576B2 (en) 2022-01-25
CA3031858A1 (en) 2018-02-15
AU2017311541B2 (en) 2020-08-13
KR102573370B1 (ko) 2023-09-01
CN116333065A (zh) 2023-06-27
CN109963864A (zh) 2019-07-02
EP3497118A1 (en) 2019-06-19
EP4324840A2 (en) 2024-02-21
SG11201901066UA (en) 2019-03-28
JP2019527715A (ja) 2019-10-03
US20250051400A1 (en) 2025-02-13
KR20230133943A (ko) 2023-09-19
DK3497117T5 (da) 2024-09-02
EP3497118B1 (en) 2022-09-14
CN109476712A (zh) 2019-03-15
KR20190044059A (ko) 2019-04-29
US20190300568A1 (en) 2019-10-03
EP4324840A3 (en) 2024-04-24
US11014967B2 (en) 2021-05-25
EP4177260A1 (en) 2023-05-10

Similar Documents

Publication Publication Date Title
JP6951417B2 (ja) アフィニティークロマトグラフィーのためのＦＣ−結合タンパク質、並びにＦｃ−結合タンパク質を含むアフィニティー分離マトリックスおよびその使用
US20230340069A1 (en) Fc binding proteins with cysteine in the c-terminal helical region
US12257530B2 (en) Fc binding proteins with cysteine in the c-terminal helical region
US20220112236A1 (en) Immunoglobulin binding proteins for affinity purification
JP2025539595A (ja) アフィニティークロマトグラフィーのための新しいリガンド

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210805

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210901

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210924

R150 Certificate of patent or registration of utility model

Ref document number: 6951417

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250